Agenus Inc.

NasdaqCM:AGEN Stock Report

Market Cap: US$109.5m

Agenus Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Garo Armen

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage19.24%
CEO tenure32yrs
CEO ownership1.1%
Management average tenure4yrs
Board average tenure3yrs

Recent management updates

Recent updates

User avatar

BOT/BAL Trials And Cost Reductions Will Shape Future Advances

Strategic cost reduction and asset monetization aim to strengthen financials and fund key projects like BOT/BAL, enhancing potential revenues and earnings.

Agenus: Novel Drugs That Just Are Not Novel

Jul 24

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

May 21
There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

May 09
Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29
Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22
Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09
News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04
A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10
Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Oct 12

Agenus New Trials Set It Up For The Long Haul

Sep 27

Agenus: It's Always Tomorrow

Sep 16

CEO Compensation Analysis

How has Garo Armen's remuneration changed compared to Agenus's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$35m

Jun 30 2025n/an/a

-US$166m

Mar 31 2025n/an/a

-US$191m

Dec 31 2024US$4mUS$715k

-US$227m

Sep 30 2024n/an/a

-US$228m

Jun 30 2024n/an/a

-US$224m

Mar 31 2024n/an/a

-US$240m

Dec 31 2023US$6mUS$710k

-US$246m

Sep 30 2023n/an/a

-US$271m

Jun 30 2023n/an/a

-US$263m

Mar 31 2023n/an/a

-US$240m

Dec 31 2022US$6mUS$689k

-US$220m

Sep 30 2022n/an/a

-US$215m

Jun 30 2022n/an/a

US$18m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$10mUS$655k

-US$24m

Sep 30 2021n/an/a

US$4m

Jun 30 2021n/an/a

-US$226m

Mar 31 2021n/an/a

-US$190m

Dec 31 2020US$6mUS$677k

-US$181m

Sep 30 2020n/an/a

-US$174m

Jun 30 2020n/an/a

-US$168m

Mar 31 2020n/an/a

-US$171m

Dec 31 2019US$10mUS$634k

-US$108m

Compensation vs Market: Garo's total compensation ($USD3.72M) is above average for companies of similar size in the US market ($USD578.00K).

Compensation vs Earnings: Garo's compensation has been consistent with company performance over the past year.

CEO

Garo Armen (72 yo)

32yrs
Tenure
US$3,717,621
Compensation

Dr. Garo H. Armen, Ph.D. founded Agenus Inc. in 1994 and has been Chief Executive Officer since 1994. He serves as an Executive Chairman at MiNK Therapeutics, Inc. Dr. Armen serves as an Executive Chairman...

Leadership Team

NamePositionTenureCompensationOwnership
Garo Armen
Founder32yrsUS$3.72m1.07%
$ 1.2m
Christine Klaskin
VP of Finance19.3yrsUS$483.48k0.069%
$ 75.6k
Steven O'Day
Chief Medical Officer5yrsUS$968.49k0.17%
$ 183.9k
Jennifer Buell
Director and President & CEO of MiNK Therapeutics4yrsno data0.058%
$ 63.6k
Craig Winter
Chief Information Officer4yrsno datano data
Zack Armen
Head of Investor Relations & Corporate Development1.2yrsno datano data
Stefanie Perna-Nacar
Chief Communications & Government Relations Officerless than a yearno datano data
Tracy Clemente
Chief People Officer4yrsno datano data
Alfred Dadson
Chief Manufacturing Officerno datano datano data
Todd Yancey
Member of Advisory Board & Chief Strategic Advisor2.2yrsno datano data
Robin Taylor
Chief Commercial Officer2.5yrsno datano data
Richard Goldberg
Chief Development Officerless than a yearno datano data
4.0yrs
Average Tenure
61.5yo
Average Age

Experienced Management: AGEN's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Garo Armen
Founder27yrsUS$3.72m1.07%
$ 1.2m
Jennifer Buell
Director and President & CEO of MiNK Therapeutics1.6yrsno data0.058%
$ 63.6k
Todd Yancey
Member of Advisory Board & Chief Strategic Advisor3yrsno datano data
Thomas Harrison
Independent Director1.4yrsUS$64.68k0.065%
$ 71.1k
Robert Stein
Member of Advisory Board3yrsUS$1.04mno data
Ulf Wiinberg
Member of Advisory Boardless than a yearUS$204.37kno data
Timothy Wright
Independent Lead Director19.1yrsUS$232.88k0.0081%
$ 8.9k
Larry Norton
Member of Advisory Board3yrsno datano data
Brian Corvese
Independent Director18.8yrsUS$490.31k0.014%
$ 14.8k
Susan Hirsch
Independent Director5.3yrsUS$138.95k0.017%
$ 19.1k
3.0yrs
Average Tenure
72yo
Average Age

Experienced Board: AGEN's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 15:55
End of Day Share Price 2026/01/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Agenus Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Mayank MamtaniB. Riley Securities, Inc.
Michael KingCitizens JMP Securities, LLC